COGT 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• The following table summarizes our results of operations for the three months ended June 30, 2026 and 2025:

• Total research and development expense increased by $8.6 million for the three months ended June 30, 2026 compared to the three months ended June 30, 2025. The increase was primarily driven by costs to support the SUMMIT, PEAK and APEX clinical programs, regulatory activities associated with potenti…

• General and administrative expenses for the three months ended June 30, 2026 were $31.8 million, compared to $13.4 million for the three months ended June 30, 2025. The increase in general and administrative expenses was driven by continued investments in commercial readiness, including personnel an…

• Interest income for the three months ended June 30, 2026 was $7.5 million, compared to $2.4 million for the three months ended June 30, 2025. The increase is due to higher invested balances in cash equivalents and marketable securities.

• Interest expense for the three months ended June 30, 2026 was $1.2 million related to the Notes and associated amortization of financing costs and the accretion of debt discount. Interest expense for the three months ended June 30, 2025 was $0.3 million related to the Credit Facility and associated …

相对上期删除的文字 · 来源:10-Q · 2026-05-05

• Comparison of the Three Months Ended March 31, 2026 and 2025

• The following table summarizes our research and development expenses for the three months ended March 31, 2026 and 2025:

• Total research and development expense increased by $12.3 million for the three months ended March 31, 2026 compared to the three months ended March 31, 2025, driven by increased early-stage, preclinical and discovery programs as we advance our pipeline of programs into Phase 1 clinical trials and I…

• General and administrative expenses for the three months ended March 31, 2026 were $28.2 million, compared to $11.9 million for the three months ended March 31, 2025. The increase in general and administrative expenses was primarily due to higher personnel and related costs associated with the build…

• Interest income for the three months ended March 31, 2026 was $7.6 million, compared to $3.0 million for the three months ended March 31, 2025. The increase is due to higher invested balances in cash equivalents and marketable securities.

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• Adoption of 10b5-1 Trading Plans by Our Directors and Officers

• During our fiscal quarter ended June 30, 2026, certain of our Directors entered into written plans for the exercise and sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in se…

• On May 28, 2026, Arlene Morris, a member of our Board of Directors, adopted a Rule 10b5-1 Trading Plan to sell up to 45,510 shares of Cogent common stock through July 31, 2027, subject to certain pricing and other conditions.

• On June 25, 2026, Dr. Karen Ferrante, a member of our Board of Directors, adopted a Rule 10b5-1 Trading Plan to sell up to 63,399 shares of Cogent common stock through June 25, 2027, subject to certain pricing and other conditions.

• In July 2026, certain of our Officers entered into Rule 10b5-1 Trading Plan as set forth below (the “Executive Rule 10b5-1 Trading Plans”). Each of the Executive Rule 10b5-1 Trading Plans is intended to facilitate long-term financial and tax planning goals. Each of these Officers intends to sell eno…

相对上期删除的文字 · 来源:10-Q · 2026-05-05

• During the fiscal quarter ended March 31, 2026, no director or Section 16 officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (in each case, as defined in Item 408(a) of Regulation S-K).